High-dose rifampicin: How do we proceed?

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 8, 2011, Pages 1133-

  Boeree, M J ^a   Van Balen, G Plemper ^a   Aarnoutse, R A ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PYRAZINAMIDE; RIFAMPICIN;

BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; HUMAN; LETTER; LUNG TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; HUMANS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 79960398072     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0198     Document Type: Letter

References (1)

1. Steingart K R, Jotblad S, Robsky K, et al. Higher-dose rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011; 15: 305-316.